| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453868 | Lung Cancer | 2018 | 6 Pages |
Abstract
No additional or unexpected safety concerns were observed, and afatinib demonstrated moderate antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib in a real-world setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Moon Ki Choi, Jin Seok Ahn, Young-Chul Kim, Byoung Chul Cho, In-Jae Oh, Sang-We Kim, Jong Seok Lee, Joo-Hang Kim, Myung-Ju Ahn, Keunchil Park,